4 recruiting, 1 active not recruiting, 1 unknown, 1 withdrawn. 3 Phase 2, 3 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Withdrawn 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Nimotuzumab Injection: new trials by email Literature Review of Nimotuzumab Injection trials Research Report on Nimotuzumab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 182 | 2026-04-20 | 2026-07-09 |
| Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma Bemcentinib, Nimotuzumab, radiotherapy - Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | Phase 3 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 370 | 2026-03-04 | 2026-04-17 |
| Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab, intensity-modulated technique（IMRT） - Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 335 | 2026-01-05 | 2026-01-12 |
| Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer Nimotuzumab, Toripalimab, Nab-paclitaxel - Head & Neck Cancer | Phase 2 | Recruiting | Tang-Du Hospital | 10 | 2025-11-15 | 2026-01-20 |
| Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer Nimotuzumab injection, Placebo, Trifluridine/tipiracil - Refractory Metastatic Colorectal Cancer | Phase 3 | Withdrawn | Biotech Pharmaceutical Co., Ltd. | 2024-04-03 | 2026-10-05 | |
| Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix Nimotuzumab Injection - Uterine Cervical Neoplasms | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 43 | 2021-05-12 | 2025-01-13 |
| Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Nimotuzumab Injection - Nasopharyngeal Carcinoma | Phase 4 | Unknown | Biotech Pharmaceutical Co., Ltd. | 2000 | 2015-08-01 | 2015-08-19 |
Head and Neck Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (3) · Colorectal Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Pathologic Complete Response (1) · Uterine Cervical Neoplasms (1)
Biotech Pharmaceutical Co., Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Shandong Cancer Hospital and Institute (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Tang-Du Hospital (1)
China (6)
Lin Shen (1) · Man Hu (1) · Shuangzheng Jia, PhD (1) · Zhao DaQing (1)